To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.

Inclusion Criteria:

• Participants must be first-generation Japanese (born in Japan and not living outside of Japan for > 10 years; both parents must be ethnically Japanese)
• Body Mass Index 18.0 to 25.0 kg/m2, inclusive
• Women must not be of nonchildbearing potential (cannot become pregnant)

Exclusion Criteria:

• Any significant acute or chronic medical illness
• History of allergy to BMS-986177 or other factor Xia inhibitors and/or formulation excipients or history of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
• History or evidence of abnormal bleeding or coagulation disorder

Other protocol defined inclusion and exclusion criteria apply